Blog

The landscape of rare diseases is evolving rapidly, with groundbreaking cell and gene therapies leading the way. These innovative treatments offer hope to patients with diseases previously considered untreatable. However, with innovation comes complexity—bringing these therapies to market isn’t just about scientific breakthroughs but also navigating unique market access challenges. This blog dives into the […]

Understanding how data and technology intersect with patient support services is essential for teams striving to improve patient outcomes. At the recent Access Patient Support Services Congress, a panel discussion titled “Optimizing Patient Services — Leveraging Data and Technology to Improve Patient Programs” gathered experienced leaders in patient services to share their valuable insights on

Eli Lilly has consistently demonstrated its dedication to precision oncology, and its latest acquisition is a testament to that commitment. The biopharma giant announced a $2.5 billion deal with Scorpion Therapeutics to acquire an experimental cancer drug targeting PI3Kα mutations. This strategic move positions Lilly to further advance its oncology portfolio and address significant unmet

Market access in the biopharma industry goes beyond delivering innovative therapies—it’s about ensuring patients receive timely and seamless access to those treatments. Two key metrics, fill rate and time-to-fill, have emerged as essential benchmarks for assessing operational efficiency, improving patient access, and aligning with strategic goals. But how can biopharma professionals effectively use these metrics

The biopharmaceutical industry continues to break new ground, redefining treatment innovation, market access, and the role of technology in healthcare. In 2024, we witnessed a wave of transformative advancements that reshaped the landscape. Staying ahead of these trends is vital for fostering innovation, navigating challenges, and seizing new opportunities.  To honor the milestones of 2024,

For over 70 years, patients with classic congenital adrenal hyperplasia (CAH) have had limited treatment options—options that often come with debilitating side effects. However, a new chapter begins with the recent FDA approval of Neurocrine Biosciences’ Crenessity, the first non-steroidal treatment for CAH. This decision heralds a groundbreaking shift in the management of this rare

Healthcare is entering an era of profound transformation, and personalized medicine stands at its forefront. This shift has not only reshaped clinical approaches but has also expanded into patient support systems. For market access and patient services teams, predictive analytics and artificial intelligence (AI) offer opportunities to revolutionize how we assist patients. By leveraging powerful

Pancreatic cancer, one of the most challenging cancers to treat, accounts for an alarming number of deaths each year, with a five-year survival rate lingering at just 13%. However, recent advancements in cancer treatment have provided a glimmer of hope. Novocure, a global oncology company, has announced groundbreaking results for its Tumor Treating Fields (TTFields)

In the rapidly evolving world of healthcare, cell and gene therapies stand out as groundbreaking advancements that hold the potential to radically change patient outcomes. For pharma manufacturers and patient services teams, navigating these complex therapies requires unprecedented strategies and innovations. This blog delves into the intricacies of the patient journey, the role of patient

In a groundbreaking move that is set to revolutionize the pharmaceutical industry, Formation Bio, Sanofi, and OpenAI have joined forces to introduce Muse, an AI tool poised to transform patient recruitment in drug development. This collaboration unites the expertise of three industry giants, each bringing unique strengths to the table, all aimed at accelerating the